Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
On Friday, Oppenheimer reiterated its Outperform rating and $30.00 price target for Entrada Therapeutics (NASDAQ:TRDA) following the company’s fourth-quarter earnings report. Entrada announced a top line of $37.4 million, primarily from collaboration revenue, and earnings per share of $0.03. These figures surpassed both Oppenheimer’s projections and the consensus estimates. According to InvestingPro data, the company maintains strong financial health with a current ratio of 6.59 and has generated $1.55 in earnings per share over the last twelve months.
Entrada Therapeutics has been advancing its development programs, and analysts at Oppenheimer expressed satisfaction with the company’s recent progress. Notably, the FDA lifted a clinical hold, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorized the commencement of the ELEVATE-44-102 and ELEVATE-44-201 studies. These studies involve the investigational drug ELEVATE-601-44, which is being developed for adults with Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping. The stock, currently trading at $11.98, has seen significant pressure recently, trading near its 52-week low of $11.35. InvestingPro subscribers have access to 11 additional investment tips for TRDA, including detailed valuation metrics and growth forecasts.
The company remains on schedule with its plans to submit global regulatory applications for two other investigational drugs, ENTR-601-50 and ENTR-601-51, in the second half of 2025 and in 2026, respectively. In addition to its neuromuscular franchise, Entrada Therapeutics has also reported positive preclinical data in other areas. The firm is preparing to announce its first clinical candidate for an ocular disease toward the end of 2025.
The reiterated Outperform rating and price target reflect Oppenheimer’s continued confidence in Entrada Therapeutics’ potential and its pipeline of development programs. The company’s recent achievements and upcoming milestones are anticipated to drive its progress in the biopharmaceutical industry.
In other recent news, Entrada Therapeutics has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 1b clinical trial for its investigational Duchenne muscular dystrophy (DMD) treatment, ENTR-601-44. This follows a similar approval from the UK’s Medicines and Healthcare Products Regulatory Agency for a related study. The ELEVATE-44-102 study aims to evaluate the safety, tolerability, and pharmacokinetics of ENTR-601-44 in adult patients with a specific genetic mutation. H.C. Wainwright has maintained a Buy rating on Entrada Therapeutics shares, with a $20 price target, highlighting the significance of these regulatory milestones. The analyst from H.C. Wainwright noted the FDA’s decision as a critical step in reducing development risks for Entrada’s pipeline. Additionally, the company’s CEO, Dipal Doshi, has been elected to the Board of Directors at Azenta, Inc., a global provider of life sciences solutions. Doshi’s extensive experience in the biotechnology and pharmaceutical sectors was praised by Azenta’s CEO, John Marotta. This development marks a strategic alignment of leadership as Azenta continues to advance in the life sciences industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.